Literature DB >> 27830857

5-Aminolevulinic acid loaded ethosomal vesicles with high entrapment efficiency for in vitro topical transdermal delivery and photodynamic therapy of hypertrophic scars.

Zheng Zhang1, Yunsheng Chen2, Heng Xu1, Yan Wo3, Zhen Zhang4, Ying Liu5, Weijie Su1, Daxiang Cui2, Yixin Zhang1.   

Abstract

Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is an alternative therapy for hypertrophic scars (HS), which destroys human hypertrophic scar fibroblasts (HSF). However, the poor permeability of ALA both in HS tissue and HSF significantly restricts the PDT of HS. To overcome these barriers, ALA-loaded ethosomal vesicles (ALA-ES) were developed by a pH gradient active loading method and characterized by morphology, entrapment efficiency (EE) and stability. Results show that prepared ALA-ES are homogenous spherical lamellar vesicles, 53 ± 7 nm in size, 50.6 ± 2.3% in EE and have excellent stability. In vitro transdermal delivery studies through HS tissue were carried out by using Franz diffusion cells. Compared to the traditional ALA hydroalcoholic solution (ALA-HA), ALA-ES achieve higher drug retention in less administration time, and fluorescence microscopy showed that ALA-ES penetrate into the deeper dermis of HS in a shorter time, indicating that ALA-ES can enhance the penetration of ALA into HS. Additionally, ALA-ES was visualized in HS tissue for the first time by transmission electron microscopy (TEM). The irregular and collapsed ALA-ES suggest that they can squeeze through narrow spaces to the target area and release ALA into HS. Taking HSF as the target, the transcellular delivery of ALA-ES into HSF cells was investigated by intracellular protoporphyrin IX (PpIX) accumulation. The efficiency of PDT for HSF cells, including the formation of reactive oxygen species (ROS) and cell apoptosis, were also well investigated. Furthermore, the detailed changes of HSF were observed by TEM. The results strongly indicate that ALA-ES can facilitate ALA penetration into HSF cells, and can cause a higher level of cell apoptosis or necrosis than ALA-HA. ALA-ES with high EE is therefore a promising transdermal delivery system for topical ALA administration and has great potential in ALA-PDT of HS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27830857     DOI: 10.1039/c6nr06872c

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  5 in total

1.  The therapy with ethosomes containing 5-fluorouracil for laryngotracheal stenosis in rabbit models.

Authors:  Xiaohui Mao; Xuefeng Cheng; Zheng Zhang; Zhaoyan Wang; Zhentao Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-21       Impact factor: 2.503

Review 2.  Ethosomes as Nanocarriers for the Development of Skin Delivery Formulations.

Authors:  Ana Cláudia Paiva-Santos; Ana Luísa Silva; Catarina Guerra; Diana Peixoto; Miguel Pereira-Silva; Mahdi Zeinali; Filipa Mascarenhas-Melo; Ricardo Castro; Francisco Veiga
Journal:  Pharm Res       Date:  2021-05-25       Impact factor: 4.200

3.  Targeting delivery and minimizing epidermal diffusion of tranexamic acid by hyaluronic acid-coated liposome nanogels for topical hyperpigmentation treatment.

Authors:  Ying Liu; Yue Han; Tingting Zhu; Xianglei Wu; Wenxin Yu; Jiafang Zhu; Ying Shang; Xiaoxi Lin; Tianlan Zhao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

4.  Biocompatible 5-Aminolevulinic Acid/Au Nanoparticle-Loaded Ethosomal Vesicles for In Vitro Transdermal Synergistic Photodynamic/Photothermal Therapy of Hypertrophic Scars.

Authors:  Zheng Zhang; Yunsheng Chen; Jiayue Ding; Chunlei Zhang; Amin Zhang; Dannong He; Yixin Zhang
Journal:  Nanoscale Res Lett       Date:  2017-12-15       Impact factor: 4.703

Review 5.  Lipid-Based Nanovesicular Drug Delivery Systems.

Authors:  Tania Limongi; Francesca Susa; Monica Marini; Marco Allione; Bruno Torre; Roberto Pisano; Enzo di Fabrizio
Journal:  Nanomaterials (Basel)       Date:  2021-12-14       Impact factor: 5.076

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.